New Zealand markets closed
  • NZX 50

    -106.26 (-0.96%)

    +0.0032 (+0.57%)

    -13.70 (-0.21%)
  • OIL

    +2.16 (+2.72%)
  • GOLD

    -0.80 (-0.05%)

The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

·3-min read

The investors in Tango Therapeutics, Inc.'s (NASDAQ:TNGX) will be rubbing their hands together with glee today, after the share price leapt 22% to US$5.22 in the week following its quarterly results. Sales hit US$5.8m in line with forecasts, although the company reported a statutory loss per share of US$0.28 that was somewhat smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Tango Therapeutics


Following the recent earnings report, the consensus from four analysts covering Tango Therapeutics is for revenues of US$21.3m in 2022, implying a considerable 11% decline in sales compared to the last 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$1.22. Before this earnings announcement, the analysts had been modelling revenues of US$22.3m and losses of US$1.32 per share in 2022. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.

There was no major change to the US$15.40average price target, suggesting that the adjustments to revenue and earnings are not expected to have a long-term impact on the business. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Tango Therapeutics at US$20.00 per share, while the most bearish prices it at US$12.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Tango Therapeutics shareholders.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 22% by the end of 2022. This indicates a significant reduction from annual growth of 7.2% over the last year. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 15% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Tango Therapeutics is expected to lag the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates revenues are expected to perform worse than the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Still, earnings are more important to the intrinsic value of the business. The consensus price target held steady at US$15.40, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Tango Therapeutics going out to 2024, and you can see them free on our platform here..

However, before you get too enthused, we've discovered 3 warning signs for Tango Therapeutics (1 is concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here